Search Within

Matthew David Hellmann

Formats
  1. Meeting Abstract (210)
  2. Journal Article (187)
  3. Review (5)
  4. Editorial (4)
  5. Research Letter (3)
  6. Guidelines (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (412)
  2. Solid Tumor Oncology Division (412)
  3. Thoracic Oncology (412)
  4. GSK Faculty (140)
  5. Department of Pathology and Laboratory Medicine (112)
  6. Weinberg Fellows (103)

More Groups

People
  1. Hira Rizvi (97)
  2. Mark Kris (71)
  3. Jamie Chaft (68)
  4. Charles Rudin (67)
  5. Jedd Wolchok (53)
  6. Gregory Riely (49)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (14)
  4. 2022 (34)
  5. 2021 (40)
  6. 2020 (55)

More Years

Publications
  1. Journal of Clinical Oncology (91)
  2. Journal of Thoracic Oncology (58)
  3. Annals of Oncology (49)
  4. Journal for ImmunoTherapy of Cancer (30)
  5. Cancer Research (24)
  6. Clinical Cancer Research (20)

More Publications

Publishers
  1. American Society of Clinical Oncology (96)
  2. Elsevier Inc. (75)
  3. American Association for Cancer Research (57)
  4. Oxford University Press (53)
  5. Biomed Central Ltd (30)
  6. Nature Publishing Group (21)

More Publishers

Results (412)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 status with outcomes for immune checkpoint inhibitors in advanced NSCLC patients
    Meeting Abstract

    Mezquita, L.; Park, W.; Arbour, K.; Auclin, E.; Hendriks, L.; Planchard, D.; Saravia, D.; Ponce Aix, S.; Nadal, E.; Audigier-Valette, C.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Concurrent mutations in STK11 and KEAP1 is associated with resistance to PD-(L)1 blockade in patients with NSCLC despite high TMB
    Meeting Abstract

    Arbour, K.; Shen, R.; Plodkowski, A.; Rizvi, H.; Ni, A.; Long, N.; Halpenny, D.; Sanchez-Vega, F.; Rudin, C.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Long-term outcomes with first-line nivolumab plus ipilimumab in advanced NSCLC: 3-year follow-up from CheckMate 012
    Meeting Abstract

    Antonia, S.; Gettinger, S.; Borghaei, H.; Goldman, J. W.; Brahmer, J.; Ready, N.; Gerber, D.; Chow, L.; Juergens, R.; Laurie, S.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of EGFR mutant lung cancers with concurrent TP53 and RB1 mutations
    Meeting Abstract

    Offin, M.; Tenet, M.; Shen, R.; Rekhtman, N.; Rizvi, H.; Hellmann, M.; Arcila, M.; Ladanyi, M.; Rudin, C.; Kris, M.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy and genomic correlates of response to anti-PD1/PD-L1 blockade in non-small cell lung cancers harboring targetable oncogenes
    Meeting Abstract

    Vokes, N.; Jimenez Alguilar, E.; Adeni, A.; Umeton, R.; Sholl, L.; Rizvi, H.; Hellmann, M.; Awad, M.; Van Allen, E.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Neoantigen targeting and T cell reshaping in resectable NSCLC patients treated with neoadjuvant PD-1 blockade
    Meeting Abstract

    El Asmar, M.; Zhang, J.; Caushi, J.; Ji, Z.; Anagnostou, V.; Cottrell, T.; Chan, H. Y.; Suri, P.; Guo, H.; Marrone, K.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes in NSCLC patients treated with first-line pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%
    Meeting Abstract

    Jomenez Alguilar, E.; Gainor, J.; Kravets, S.; Khosrowjerdi, S.; Lydon, C.; Adeni, A.; Subegdjo, S.; Rizvi, H.; Hellmann, M.; Awad, M.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy/safety of entinostat (ENT) and pembrolizumab (PEMBRO) in NSCLC patients previously treated with anti-PD-(L) 1 therapy
    Meeting Abstract

    Hellmann, M.; Jänne, P.; Opyrchal, M.; Hafez, N.; Raez, L.; Gabrilovich, D.; Wang, F.; Ordentlich, P.; Brouwer, S.; Sankoh, S.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC
    Meeting Abstract

    Hellmann, M. D.; Antonia, S. J.; Balmanoukian, A. S.; Brahmer, J. R.; Ou, S. H. I.; Kim, S. W.; Ahn, M. J.; Kim, D. W.; Gutierrez, M.; Liu, S. V.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • CheckMate 227: Nivolumab + ipilimumab vs platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB)
    Meeting Abstract

    Gerber, D. E.; Reck, M.; Hellmann, M. D.; Paz-Ares, L.; Borghaei, H.; Brahmer, J.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F.; Ramalingam, S. S.
    Journal of Oncology Navigation & Survivorship (2018)

    Fulltext@MSK | Save